ANAPTYSBIO, INC. Stock-Based Compensation
ANAPTYSBIO, INC. (ANAB) reported Stock-Based Compensation of $8.32 million for the 6-month period ending 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-09-21
- ANAPTYSBIO, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was -$5.90M.
- ANAPTYSBIO, INC. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $14.22M, a 55.05% increase year-over-year.
- ANAPTYSBIO, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was -$23.79M.
- ANAPTYSBIO, INC. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $24.56M, a 199.90% increase year-over-year.
- ANAPTYSBIO, INC. share-based payment arrangement, noncash expense for fiscal 2025 was $3.77M, a 47.76% decline from fiscal 2024.
- ANAPTYSBIO, INC. share-based payment arrangement, noncash expense for fiscal 2024 was $7.22M, a 78.25% decline from fiscal 2023.
- ANAPTYSBIO, INC. share-based payment arrangement, noncash expense for fiscal 2023 was $33.20M, a 21.38% increase from fiscal 2022.
- ANAPTYSBIO, INC. share-based payment arrangement, noncash expense for fiscal 2022 was $27.36M, a 78.25% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 6 month as first filed | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month | Share-based Payment Arrangement, Noncash Expense 12 month as first filed |
|---|---|---|---|---|---|---|
| 2026-06-30 | -$5.90M derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | $8.32M 10-KT · filed 2026-09-21 | -$15.47M derived: sum of 3 quarters · filed 2026-09-21 | $9.09M derived: sum of 4 quarters · filed 2026-09-21 | ||
| 2026-03-31 | $14.22M 10-Q · filed 2026-05-12 | -$9.58M derived: sum of 2 quarters · filed 2026-09-21 | $14.98M derived: sum of 3 quarters · filed 2026-09-21 | $8.82M derived: sum of 4 quarters · filed 2026-09-21 | ||
| 2025-12-31 | -$23.79M derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | $765.00K derived: sum of 2 quarters · filed 2026-09-21 | -$5.40M derived: sum of 3 quarters · filed 2026-09-21 | $3.77M 10-KT · filed 2026-09-21 | $36.07M 10-K · filed 2026-03-03 | |
| 2025-09-30 | $24.56M derived: 10-Q 9 month − 10-KT 6 month · filed 2025-11-04 | $18.40M derived: sum of 2 quarters · filed 2026-09-21 | $27.57M 10-Q · filed 2025-11-04 | $8.92M derived: sum of 4 quarters · filed 2026-09-21 | ||
| 2025-06-30 | -$6.16M derived: 10-KT 6 month − 10-Q 3 month · filed 2026-09-21 | $3.01M 10-KT · filed 2026-09-21 | $18.41M 10-Q · filed 2025-08-06 | -$15.64M derived: sum of 3 quarters · filed 2026-09-21 | -$7.45M derived: sum of 4 quarters · filed 2026-09-21 | |
| 2025-03-31 | $9.17M 10-Q · filed 2026-05-12 | -$9.47M derived: sum of 2 quarters · filed 2026-09-21 | -$1.28M derived: sum of 3 quarters · filed 2026-09-21 | $6.26M derived: sum of 4 quarters · filed 2026-09-21 | ||
| 2024-12-31 | -$18.64M derived: 10-KT 12 month − 10-Q 9 month · filed 2026-09-21 | -$10.45M derived: sum of 2 quarters · filed 2026-09-21 | -$2.91M derived: sum of 3 quarters · filed 2026-09-21 | $7.22M 10-KT · filed 2026-09-21 | $34.05M 10-K · filed 2025-02-27 | |
| 2024-09-30 | $8.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $15.73M derived: sum of 2 quarters · filed 2025-11-04 | $25.86M 10-Q · filed 2025-11-04 | $33.98M derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2024-06-30 | $7.54M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $17.68M 10-Q · filed 2025-08-06 | $25.79M derived: sum of 3 quarters · filed 2026-03-03 | $33.59M derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2024-03-31 | $10.13M 10-Q · filed 2025-05-05 | $18.24M derived: sum of 2 quarters · filed 2026-03-03 | $26.05M derived: sum of 3 quarters · filed 2026-03-03 | $34.48M derived: sum of 4 quarters · filed 2026-03-03 | ||
| 2023-12-31 | $8.11M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-03 | $15.92M derived: sum of 2 quarters · filed 2026-03-03 | $24.34M derived: sum of 3 quarters · filed 2026-03-03 | $33.20M 10-K · filed 2026-03-03 | ||
| 2023-09-30 | $7.81M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | $16.23M derived: sum of 2 quarters · filed 2024-11-05 | $25.09M 10-Q · filed 2024-11-05 | $31.78M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-06-30 | $8.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $17.29M 10-Q · filed 2024-08-05 | $23.97M derived: sum of 3 quarters · filed 2025-02-27 | $30.24M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2023-03-31 | $8.86M 10-Q · filed 2024-05-09 | $15.54M derived: sum of 2 quarters · filed 2025-02-27 | $21.82M derived: sum of 3 quarters · filed 2025-02-27 | $28.47M derived: sum of 4 quarters · filed 2025-02-27 | ||
| 2022-12-31 | $6.68M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $12.96M derived: sum of 2 quarters · filed 2025-02-27 | $19.61M derived: sum of 3 quarters · filed 2025-02-27 | $27.36M 10-K · filed 2025-02-27 | ||
| 2022-09-30 | $6.27M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $12.93M derived: sum of 2 quarters · filed 2023-11-02 | $20.67M 10-Q · filed 2023-11-02 | $24.65M derived: sum of 4 quarters · filed 2024-03-11 | ||
| 2022-06-30 | $6.66M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $14.40M 10-Q · filed 2023-08-07 | $18.38M derived: sum of 3 quarters · filed 2024-03-11 | $22.74M derived: sum of 4 quarters · filed 2024-03-11 | ||
| 2022-03-31 | $7.74M 10-Q · filed 2023-05-11 | $11.72M derived: sum of 2 quarters · filed 2024-03-11 | $16.08M derived: sum of 3 quarters · filed 2024-03-11 | $19.77M derived: sum of 4 quarters · filed 2024-03-11 | ||
| 2021-12-31 | $3.98M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-11 | $8.34M derived: sum of 2 quarters · filed 2024-03-11 | $12.03M derived: sum of 3 quarters · filed 2024-03-11 | $15.35M 10-K · filed 2024-03-11 | ||
| 2021-09-30 | $4.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $8.05M derived: sum of 2 quarters · filed 2022-11-08 | $11.37M 10-Q · filed 2022-11-08 | |||
| 2021-06-30 | $3.69M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | $7.00M 10-Q · filed 2022-08-08 | ||||
| 2021-03-31 | $3.31M 10-Q · filed 2022-05-04 | |||||
| 2017-12-31 | $4.38M 10-K · filed 2018-03-05 | |||||
| 2016-12-31 | $1.16M 10-K · filed 2018-03-05 | |||||
| 2015-12-31 | $604.00K 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |